On the problem of the cardiotoxicity of epirubicin-cisplatin
Lechner, W.; Zechmann, W.; Mayr, P.; Reider, W.; Marth, C.
Zentralblatt für Gynakologie 110(7): 429-432
1988
ISSN/ISBN: 0044-4197 PMID: 3164959 Document Number: 307472
Cardiotoxicity is supposed to be the most important limiting factor in chemotherapy with anthracycline derivatives. The left ventricular ejection fraction was measured several times by means of radionuclid - scintigraphy in 24 patients treated with epirubicin - cisplatinum. Pathologic values have been found only in 3 patients, but no correlation with age, cumulative dose or dose/m2 of body surface could be demonstrated.
Document emailed within 1 workday
Related Documents
Rivero, O.; Mordeglia, F. 1987: Epirubicin: an anthracycline of minor cardiotoxicity Medicina 47(3): 320-321Zygulska, A.L.; Pawlega, J. 2008: Assessment of the value of PEF (cisplatin, epirubicin, 5 fluorouracil) in advanced extrahepatic biliary tract and pancreatic cancer Przeglad Lekarski 65(12): 825-828
Unsal, M.; Erturk, D. 2003: Cisplatin and etoposide alternating ifosfamide, vincristine, epirubicin in small cell lung cancer Saudi Medical Journal 24(6): 628-631
Takezako, Y.; Okusaka, T.; Ueno, H.; Ikeda, M.; Morizane, C.; Najima, M. 2008: Phase Ii study of cisplatin, epirubicin and continuous infusion of 5-fluorouracil in patients with advanced intrahepatic cholangiocellular carcinoma (ICC) Hepato-Gastroenterology 55(85): 1380-1384
Mambrini, A.; Pacetti, P.; Del Freo, A.; Seta, R.D.; Pezzuolo, D.; Torri, T.; Orlandi, M.; Tartarini, R.; Cantore, M. 2009: Gemcitabine-capecitabine plus intra-arterial epirubicin-cisplatin in pretreated pancreatic cancer patients: a phase i study Anticancer Research 29(5): 1547-1549
Chen, Y.M.; Perng, R.P.; Yang, K.Y.; Wu, H.W.; Lin, W.C.; Liu, J.M.; Tsai, C.M.; Whang-Peng, J. 2000: Combination chemotherapy with tamoxifen, ifosfamide, epirubicin and cisplatin in extensive-disease small-cell lung cancer Zhonghua Yi Xue Za Zhi 63(8): 605-611
Rassweiler, J.; Rüther, U.; Bäuerle, K.; Bub, P.; Jipp, P.; Eisenberger, F. 1989: Polychemotherapy using the M-VEC protocol (methotrexate, vinblastine, epirubicin, cisplatin) in advanced urinary bladder cancer--effectiveness and toxicity Der Urologe. Ausg. a 28(1): 25-30
Rosell, R.; Gómez-Codina, J.; Anton, A.; Sánchez, J.J.; Vadell, C. 1994: Escalating high-dose epirubicin plus cisplatin in small cell lung cancer with granulocyte-macrophage colony-stimulating factor use when appropriate Seminars in Oncology 21(1 Suppl 1: 48-53
Pispirigos, K.; Paradelis, A.G.; Karakiulakis, G. 1997: Evaluation of cardiac subacute toxicity of epirubicin, chlorambucil, cisplatin, methotrexate and a homo-aza-steroid ester with antitumor activity in rats using serum biochemical parameters Arzneimittel-Forschung 47(1): 92-96
Nolte, H. 1986: The problem of the cardiotoxicity of bupivacaine 0.75% Regional-Anaesthesie 9(3): 57-59
Kobayashi, H. 1985: Cisplatin and ovarian carcinoma--early detection of cisplatin-induced nephrotoxicity Nihon Sanka Fujinka Gakkai Zasshi 37(6): 888-896
Makhnova, E.V. 2003: Combination chemotherapy with Hemzar (gemcitabine) and cisplatin for relapsing and cisplatin-resistant ovarian cancer Voprosy Onkologii 49(1): 60-65
Zhao, J. 1985: Cisplatin or combined cisplatin and 60Co radiation in the treatment of advanced lung cancer--report of 145 cases Zhonghua Zhong Liu Za Zhi 7(4): 283-285
González-Larriba, J.L.; Garcia Carbonero, I.; Sastre Valera, J.; Perez Segura, P.; Diaz-Rubio, E. 1997: Neoadjuvant therapy with cisplatin/fluorouracil vs cisplatin/UFT in locally advanced squamous cell head and neck cancer Oncology 11(9 Suppl 10: 90-97
Kudoh, K.; Kita, T.; Hirata, J.; Ishii, K.; Hiramatsu, H.; Kikuchi, Y.; Nagata, I. 1994: Potentiation of cisplatin sensitivity of cisplatin-resistant human ovarian cancer cell lines by L-buthionine-S,R-sulfoximine Nihon Sanka Fujinka Gakkai Zasshi 46(6): 525-532
Yu, Y.; Zhang, X.; Tian, H.; Zhang, Z.; Tian, Y. 2018: Knockdown of long non-coding RNA HOTAIR increases cisplatin sensitivity in ovarian cancer by inhibiting cisplatin-induced autophagy Journal of BUON: Official Journal of the Balkan Union of Oncology 23(5): 1396-1401
Johnson, S.W.; Swiggard, P.A.; Handel, L.M.; Brennan, J.M.; Godwin, A.K.; Ozols, R.F.; Hamilton, T.C. 1994: Relationship between platinum-DNA adduct formation and removal and cisplatin cytotoxicity in cisplatin-sensitive and -resistant human ovarian cancer cells Cancer Research 54(22): 5911-5916
Zhang, M-Chun.; Hu, C-Ping.; Chen, Q. 2006: Effect of down-regulation of survivin gene on apoptosis and cisplatin resistance in cisplatin resistant human lung adenocarcinoma A549/CDDP cells Zhonghua Zhong Liu Za Zhi 28(6): 408-412
Sukhaboon, J.; Porapakkhan, P.; Penpattanagul, S. 2009: Randomized comparison of fluorouracil plus cisplatin vs. cisplatin as an adjunct to radiation therapy in stage IIB-IVA squamous cell carcinoma of the cervix: pilot study Journal of the Medical Association of Thailand 92(8): 1072-1076
Fichtinger-Schepman, A.M.; Vendrik, C.P.; van Dijk-Knijnenburg, W.C.; de Jong, W.H.; van der Minnen, A.C.; Claessen, A.M.; van der Velde-Visser, S.D.; de Groot, G.; Wubs, K.L.; Steerenberg, P.A. 1989: Platinum concentrations and DNA adduct levels in tumors and organs of cisplatin-treated LOU/M rats inoculated with cisplatin-sensitive or -resistant immunoglobulin M immunocytoma Cancer Research 49(11): 2862-2867